医学
糖尿病
赖诺普利
肌酐
肾脏疾病
内科学
2型糖尿病
内分泌学
疾病
发病机制
罗格列酮
肾功能
泌尿科
血管紧张素转换酶
血压
作者
Shannon M. Harlan,Kathleen M. Heinz-Taheny,John M. Sullivan,Tao Wei,Hana E. Baker,Dianna L. Jaqua,Zhonghua Qi,Martin S. Cramer,Tatiyana L. Shiyanova,Matthew D. Breyer,Josef G. Heuer
出处
期刊:Journal of The American Society of Nephrology
日期:2017-10-23
卷期号:29 (2): 477-491
被引量:31
标识
DOI:10.1681/asn.2017040385
摘要
Progress in research and developing therapeutics to prevent diabetic kidney disease (DKD) is limited by a lack of animal models exhibiting progressive kidney disease. Chronic hypertension, a driving factor of disease progression in human patients, is lacking in most available models of diabetes. We hypothesized that superimposition of hypertension on diabetic mouse models would accelerate DKD. To test this possibility, we induced persistent hypertension in three mouse models of type 1 diabetes and two models of type 2 diabetes by adeno-associated virus delivery of renin (ReninAAV). Compared with LacZAAV-treated counterparts, ReninAAV-treated type 1 diabetic Akita/129 mice exhibited a substantial increase in albumin-to-creatinine ratio (ACR) and serum creatinine level and more severe renal lesions. In type 2 models of diabetes (C57BKLS db/db and BTBR ob/ob mice), compared with LacZAAV, ReninAAV induced significant elevations in ACR and increased the incidence and severity of histopathologic findings, with increased serum creatinine detected only in the ReninAAV-treated db/db mice. The uninephrectomized ReninAAV db/db model was the most progressive model examined and further characterized. In this model, separate treatment of hyperglycemia with rosiglitazone or hypertension with lisinopril partially reduced ACR, consistent with independent contributions of these disorders to renal disease. Microarray analysis and comparison with human DKD showed common pathways affected in human disease and this model. These results identify novel models of progressive DKD that provide researchers with a facile and reliable method to study disease pathogenesis and support the development of therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI